var data={"title":"Methyltestosterone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methyltestosterone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6568?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methyltestosterone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methyltestosterone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195469\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Android;</li>\n      <li>Methitest;</li>\n      <li>Testred</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195485\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Androgen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195472\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In adult men with androgen deficiency syndromes (eg, hypogonadism), withhold initial treatment with hematocrit &gt;50% (discontinue therapy if hematocrit exceeds 54%), untreated obstructive sleep apnea, uncontrolled severe heart failure, or with severe untreated BPH with IPSS symptom score &gt;19 (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic (females):</b> Oral: 50 to 200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delayed puberty (males):</b> Oral: 10 to 50 mg daily; limit treatment duration to 4 to 6 months; use lower range of dosing and individualize dose based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypogonadotropic hypogonadism (congenital or acquired) and primary hypogonadism (congenital or acquired) (males):</b> Oral: Initial: 10 to 50 mg daily; individualize dose based on response and tolerability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25479280\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Delayed puberty: Adolescent males:</b> Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypogonadotropic hypogonadism (congenital or acquired) and primary hypogonadism (congenital or acquired):</b> Adolescent males: Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195473\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570417\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, patients with renal disease may be at an increased risk of fluid retention.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570418\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, patients with hepatic disease may be at an increased risk of fluid retention.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195457\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Android: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Testred: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methitest: 10 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195442\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195487\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28107296\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104554\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195459\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Males:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Delayed puberty:</b> To stimulate puberty in carefully selected males with clearly delayed puberty.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Hypogonadotropic hypogonadism (congenital or acquired):</b> Treatment of idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Primary hypogonadism (congenital or acquired):</b> Treatment of testicular failure caused by cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Females:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Breast cancer, metastatic:</b> Secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal; has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195493\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MethylTESTOSTERone may be confused with medroxyPROGESTERone, methylPREDNISolone</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Methyltestosterone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its potential for cardiac problems; use is contraindicated in men with prostate cancer. Avoid unless methyltestosterone is used for confirmed hypogonadism with clinical symptoms (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195449\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, headache, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, androgenetic alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, gynecomastia (males), hirsutism (females), hypercalcemia, hypercholesterolemia, menstrual disease (includes amenorrhea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Benign prostatic hypertrophy (males), impotence (males), mastalgia (females), oligospermia (males; at high doses), priapism (males), testicular atrophy (males), virilization (males and females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Clotting factors suppression, polycythemia, prostate carcinoma (males)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal liver function tests, cholestatic hepatitis, hepatic insufficiency, hepatic necrosis, jaundice, peliosis hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, hepatocellular neoplasm, hepatotoxicity (idiosyncratic; Chalasani 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195462\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Men with breast cancer or with known or suspected prostate cancer; women who are or may become pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195446\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Available studies are inconclusive regarding the risk of developing major adverse cardiovascular events (MACE) such as nonfatal MI, stroke, or cardiovascular death following testosterone use. Studies have suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy (Basaria 2010; Finkle 2014; Vigen 2013). The Endocrine Society suggests it may be prudent to avoid testosterone therapy in men who have experienced a cardiovascular event (eg, MI, stroke, acute coronary syndrome) in the past six months (The Endocrine Society 2014). These risks are currently under review by the FDA (Drug Safety Communication 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gynecomastia: May cause gynecomastia which may persist in patients treated for hypogonadism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis, hepatic neoplasms including hepatocellular carcinoma, cholestatic hepatitis, and jaundice. Discontinue if cholestatic hepatitis with jaundice or abnormal liver function tests occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: May cause oligospermia and reduced ejaculatory volume after prolonged administration or excessive dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polycythemia: May increase hematocrit requiring dose adjustment or discontinuation. Withhold initial treatment in patients with hematocrit &gt;50%. Discontinue therapy if hematocrit exceeds 54%; may reinitiate at lower dose (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Priapism or excessive sexual stimulation may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benign prostatic hyperplasia (BPH): Androgens may worsen BPH; do not use in patients with severe lower urinary tract symptoms [(AUA)/International Prostate Symptom Score (IPSS) &gt; 19] (Endocrine Society [Bhasin 2010]). Discontinue therapy if urethral obstruction develops in patients with BPH (use lower dose if restarted).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: May cause hypercalcemia (by stimulating osteolysis) in patients with breast cancer; discontinue if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac impairment; may cause fluid retention. Treatment of androgen deficiency syndromes is not recommended for men with uncontrolled or poorly controlled heart failure (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: May increase the risk of prostate cancer. Withhold therapy pending urological evaluation in patients with palpable prostate nodule or induration, PSA &gt;4 ng/mL, or PSA &gt;3 ng/mL in men at high risk of prostate cancer (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep apnea: May potentiate sleep apnea in some male patients, especially those with risk factors (eg, obesity or chronic lung disease). Withhold initial treatment in patients with untreated obstructive sleep apnea (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May be at greater risk for prostatic hyperplasia, and prostate cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May accelerate bone maturation (without producing compensatory gain in linear growth) and premature closure of the epiphyses in children; in prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. Use with caution in males with delayed puberty.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women: During treatment for metastatic breast cancer, women should be monitored for signs of virilization; discontinue if mild virilization is present to prevent irreversible symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: Anabolic steroids may be abused, typically at doses higher than recommended and in combination with other anabolic androgenic steroids; abuse may be associated with serious cardiovascular and psychiatric adverse reactions. Inform patients of the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids; if abuse is suspected, check serum testosterone levels (testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives). Consider the possibility of abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence: Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented; however dependence may occur when used outside of approved dosage/indications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299703\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195451\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9640&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195452\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13388443\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are or may become pregnant. May cause virilization of the external genitalis of the female fetus, including clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of masculinization is dose related and most likely to occur when androgens are administered in the first trimester. If a patient becomes pregnant while taking androgens, she should be counseled on the potential hazard to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616287\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if methyltestosterone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195454\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to treatment initiation: Confirm hypogonadism by measuring morning serum testosterone on at least 2 separate days. Liver function tests, lipid panel, hemoglobin and hematocrit (withhold initial treatment with hematocrit &gt;50%) (Endocrine Society [Bhasin 2010]). PSA and prostate exam in men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL.</p>\n    <p style=\"text-indent:0em;\">During treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liver function tests, lipid panel, hemoglobin and hematocrit (at 3 to 6 months then annually); discontinue therapy if hematocrit exceeds 54% (Endocrine Society [Bhasin 2010]). Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3 to 6 months after initiation and then annually; monitor for cardiovascular events closely during therapy. Monitor serum testosterone 3 to 6 months after initial dose titration (if applicable) then annually.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Bone mineral density:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prepubertal children: Radiologic examination of wrist and hand every 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypogonadal men with osteoporosis or low trauma fracture: Monitor after 1 to 2 years of therapy (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PSA: In men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL, PSA and prostate exam at 3 to 6 months, then as based on current guidelines. Withhold treatment pending urological evaluation in patients with palpable prostate nodule or induration or PSA &gt;4 ng/mL or if PSA &gt;3 ng/mL in men at high risk of prostate cancer (Endocrine Society [Bhasin 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195445\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous androgen stimulates receptors in organs and tissues to promote growth and development of male sex organs and maintains secondary sex characteristics in androgen-deficient males</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195461\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% bound to sex hormone-binding globulin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Variable: 10 to 100 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~90%); feces (~6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195463\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Android Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $17,788.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (MethylTESTOSTERone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $8,389.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Testred Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $9,394.67</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195464\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Build (TW);</li>\n      <li>Gynosterone (IL);</li>\n      <li>Menwin (LK);</li>\n      <li>Mesteron (PL);</li>\n      <li>Testormon (PT);</li>\n      <li>Testotonic B (IL);</li>\n      <li>Testovis (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Android (methyltestosterone) capsules [prescribing information]. Bridgewater, NJ: Valeant; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. <i>N Engl J Med</i>. 2010;363(2):109-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/20592293/pubmed\" target=\"_blank\" id=\"20592293\">20592293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2010;95:2536-2559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/20525905/pubmed\" target=\"_blank\" id=\"20525905\">20525905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Endocrine Society news release. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks. https://www.endocrine.org/news-room/press-release-archives/2014/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks. Updated February 7, 2014. Accessed April 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Drug Safety Communications. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Food and Drug Administration website. <a href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf</a>. Published January 31, 2014. Accessed February 5, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. <i>PLoS One</i>. 2014;9(1):e85805.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24489673/pubmed\" target=\"_blank\" id=\"24489673\">24489673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methitest (methyltestosterone) [prescribing information]. Hayward, CA: Impax Generics; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testred (methyltestosterone) capsules [prescribing information]. Bridgewater, NJ: Valeant; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vigen R, O'Donnell CI, Bar&oacute;n AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels [published correction appears in <i>JAMA</i>. 2014;311(9):967]. <i>JAMA</i>. 2013;310(17):1829-1836.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24193080/pubmed\" target=\"_blank\" id=\"24193080\">24193080</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9640 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195469\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F195485\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F195472\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F25479280\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F195473\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16570417\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570418\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195457\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F195442\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F195487\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28107296\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104554\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F195459\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195493\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195449\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195462\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195446\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299703\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195451\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195452\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13388443\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616287\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F195454\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195445\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F195461\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195463\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195464\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9640|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methyltestosterone-patient-drug-information\" class=\"drug drug_patient\">Methyltestosterone: Patient drug information</a></li></ul></div></div>","javascript":null}